Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Randomized, Open-label Study to Evaluate the Pharmacokinetic, Safety and Efficacy of Peginterferon Alfa-2b Injection in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.

NCT06552429 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.

NCT NCT06552429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06552429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Randomized, Open-label Study to Evaluate the Pharmacokinetic, Safety and Efficacy of Peginterferon Alfa-2b Injection in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.
Lead sponsor
Xiamen Amoytop Biotech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2024
Completion date
September 30, 2027
Enrollment
27 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia